Mrs Megan C Ortolano, PT | |
84 Dunham Hollow Road, East Nassau, NY 12062 | |
(518) 526-9301 | |
Not Available |
Full Name | Mrs Megan C Ortolano |
---|---|
Gender | Female |
Speciality | Physical Therapist |
Location | 84 Dunham Hollow Road, East Nassau, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164694865 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | 0048291 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Megan C Ortolano, PT 84 Dunham Hollow Road, East Nassau, NY 12062 Ph: (518) 526-9301 | Mrs Megan C Ortolano, PT 84 Dunham Hollow Road, East Nassau, NY 12062 Ph: (518) 526-9301 |
News Archive
In its latest pioneering effort to harness the power of focused ultrasound to battle disease, the University of Virginia Health System is examining the scalpel-free surgery's potential to enable the body to identify and destroy metastatic breast cancer cells.
Two innovative programs designed to improve the availability of emerging medical technologies that can help patients receive more effective, efficient and personalized health care are advanced in a commentary written by a team of scientists and policy experts, including seven from Arizona State University, and published today in Science Translational Medicine.
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended June 30, 2015.
The decision-making process in West Virginia was long and involved, while the outcome of Arizona Gov. Jan Brewer's push for the expansion is still in flux. In Ohio, advocates are considering taking the proposal to the voters if the legislature won't pass it.
Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets
› Verified 7 days ago